EvidenceHealthVitaminsSupplementsVitamin D
Vitamin D3 supplementation in generally healthy adults: primary results of the VITAL trial
- Study type:
- Large randomised, double-blind, placebo-controlled primary prevention trial (2×2 factorial design with vitamin D3 and omega‑3) in generally healthy adults.
- Topic:
- Vitamin D supplementation and disease prevention
- Added:
- 2026-04-17
- Status:
- published
Strength of evidence
Moderate
Source
Manson JE et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380:33–44.
Open original studyThe VITAL trial randomised over 25,000 generally healthy US adults to **vitamin D3 (2,000 IU/day)** or placebo (and separately omega‑3 or placebo) and followed them for a median of about 5 years. Vitamin D3 **did not significantly reduce** the incidence of major cardiovascular events, invasive cancer, or all‑cause mortality compared with placebo. This is a large, well-conducted RCT with hard clinical endpoints; it provides **moderate-quality evidence** that routine vitamin D3 supplementation at this dose in an unselected population does **not** deliver the broad preventive benefits often claimed.
Key findings
- Participants: ~25,871 men and women without cancer or cardiovascular disease at baseline.
- Intervention: vitamin D3 2,000 IU/day vs placebo, in a 2×2 factorial design with omega‑3 fatty acids.
- Follow-up: median ~5.3 years.
- Primary endpoints: Major cardiovascular events (MI, stroke, cardiovascular death) – **no significant difference** between vitamin D and placebo. Invasive cancer of any type – **no significant difference**.
- Secondary endpoints: All-cause mortality – **no meaningful reduction**. Some small subgroup signals and site-specific cancer findings, but not strong or consistent enough to change the overall null result.
- Safety: No major increase in kidney stones, hypercalcaemia or other classic vitamin D toxicity at this dose.
Background
- Vitamin D (cholecalciferol) has been promoted as a near-universal preventive agent for cancer, cardiovascular disease and many other conditions. Observational studies have repeatedly shown that lower serum 25(OH)D levels are associated with higher disease risk. This led to the hypothesis that supplementing vitamin D in the general population would reduce major clinical events.
- The VITAL trial was designed as a definitive large-scale test of this hypothesis in generally healthy adults.
Methods
- **Population:** 25,871 US men (≥50 years) and women (≥55 years) without cardiovascular disease or cancer at baseline.
- **Design:** Randomised, double-blind, placebo-controlled, 2×2 factorial: Vitamin D3 2,000 IU/day vs vitamin D placebo; Omega-3 fatty acids 1 g/day vs omega-3 placebo.
- **Follow-up:** Median of approximately 5.3 years.
- **Primary endpoints:** Major cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death); Invasive cancer of any type.
- **Secondary endpoints:** Site-specific cancers, cancer mortality, total mortality, and other cardiovascular outcomes.
Results
- **Major cardiovascular events:** No significant reduction in the vitamin D group compared with placebo.
- **Invasive cancer:** No significant reduction in total invasive cancer incidence with vitamin D3.
- **All-cause mortality:** Point estimates were slightly favourable but **not large or robust enough** to be considered a clear benefit.
- **Subgroups:** Some exploratory analyses suggested possible benefits in select subgroups (e.g. people with lower baseline vitamin D levels), but these were not conclusive and were not primary endpoints.
- **Safety:** Incidence of serious adverse events, including kidney stones and hypercalcaemia, was not dramatically increased at the 2,000 IU/day dose.
Interpretation
- In a large, generally healthy adult population, daily vitamin D3 supplementation at 2,000 IU did **not** significantly reduce: major cardiovascular events, overall invasive cancer incidence, or all-cause mortality over ~5 years.
- The trial was randomised, double-blind, and used **hard clinical endpoints**, which makes its null results important. It strongly contradicts marketing claims that vitamin D, by itself and at common supplement doses, is a powerful general preventive agent against heart disease and cancer in unselected adults.
- From a WorthDay perspective: Evidence quality is **🟡 Moderate**: strong design for the specific dose and population tested, clear hard endpoints, but still limited to ~5 years and does not cover very deficient or high-risk groups separately. It provides **negative evidence** against broad preventive promises, not positive proof of benefit.
Limitations
- Participants were mostly **not severely vitamin D deficient** at baseline; results may not apply to people with extreme deficiency or specific clinical conditions.
- The dose (2,000 IU/day) and the follow-up (~5 years) may not reflect all possible regimens or longer-term effects.
- The 2×2 factorial with omega-3 introduces some complexity, although main effects for vitamin D were analysed appropriately.
- As with any large trial, small subgroup effects cannot be ruled out but are not robust enough for strong claims.
WorthDay perspective
- S0053 is a key piece of **negative evidence**: in a large, generally healthy adult population, routine vitamin D3 supplementation at 2,000 IU/day did **not** deliver the dramatic preventive benefits often advertised.
- Under WorthDay Evidence Criteria, this RCT makes it **unjustified** to sell vitamin D as a broad "anti-cancer" or "cardio-protective" pill for the average adult.
- For WorthDay users, S0053 supports: caution towards supplement marketing, focusing more on foundational lifestyle Elements (light exposure, movement, nutrition patterns) rather than assuming a pill will meaningfully change hard outcomes in the general population.
- It does **not** exclude the possibility that targeted vitamin D therapy in clearly deficient or special-risk individuals could be useful; it simply shows that **mass supplementation of generally healthy adults is not a magic shield**.
Permalink: https://www.worth-day.com/science-compass/s0053-vitamin-d3-supplementation-in-generally-healthy-adults
Related studies
- Calcium plus vitamin D in postmenopausal women: more kidney stones, limited fracture benefitS0056
- Monthly high-dose vitamin D in older adults: more falls with higher dosesS0055
- Annual high-dose vitamin D3 in older women: increased risk of falls and fracturesS0054
- β‑Carotene Supplements & Lung Cancer in Male Smokers (ATBC)S0035
Science meets practice